Squamous Cell Cancers: A Unified Perspective on Biology and Genetics

Cancer Cell

Volumn 29, Issue 5, 2016, Pages 622-637

  Dotto, G Paolo ^a,b   Rustgi, Anil K ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SOX2;

CARCINOGENESIS; CELL CYCLE REGULATION; CELL FATE; EPIGENETICS; HUMAN; INFECTION; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; BIOLOGICAL MODEL; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DRINKING BEHAVIOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MUTATION;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFECTION; MODELS, GENETIC; MUTATION; SMOKING; ULTRAVIOLET RAYS;

EID: 84975259969     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.04.004     Document Type: Review

References (184)

1. Adhikary G., Grun D., Balasubramanian S., Kerr C., Huang J.M., Eckert R.L. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis 2015, 36:800-810.
2. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
3. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
4. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
5. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B 2001, 63:8-18.
6. Arnault J.P., Mateus C., Escudier B., Tomasic G., Wechsler J., Hollville E., Soria J.C., Malka D., Sarasin A., Larcher M., et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin. Cancer Res. 2012, 18:263-272.
7. Bachelor M.A., Bowden G.T. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin. Cancer Biol. 2004, 14:131-138.
8. Bajaj J., Maliekal T.T., Vivien E., Pattabiraman C., Srivastava S., Krishnamurthy H., Giri V., Subramanyam D., Krishna S. Notch signaling in CD66+ cells drives the progression of human cervical cancers. Cancer Res. 2011, 71:4888-4897.
9. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., Kim S.Y., Wardwell L., Tamayo P., Gat-Viks I., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 2009, 41:1238-1242.
10. Behrens C., Solis L.M., Lin H., Yuan P., Tang X., Kadara H., Riquelme E., Galindo H., Moran C.A., Kalhor N., et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin. Cancer Res. 2013, 19:6556-6565.
11. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
12. Bigarella C.L., Liang R., Ghaffari S. Stem cells and the impact of ROS signaling. Development 2014, 141:4206-4218.
13. Botelho M.C., Machado J.C., Brindley P.J., Correia da Costa J.M. Targeting molecular signaling pathways of Schistosoma haemotobium infection in bladder cancer. Virulence 2011, 2:267-279.
14. Boumahdi S., Driessens G., Lapouge G., Rorive S., Nassar D., Le Mercier M., Delatte B., Caauwe A., Lenglez S., Nkusi E., et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014, 511:246-250.
15. Brand T.M., Iida M., Wheeler D.L. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol. Ther. 2011, 11:777-792.
16. Brooks P.J., Zakhari S. Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis. Environ. Mol. Mutagen. 2014, 55:77-91.
17. Brooks Y.S., Ostano P., Jo S.H., Dai J., Getsios S., Dziunycz P., Hofbauer G.F., Cerveny K., Chiorino G., Lefort K., et al. Multifactorial ERbeta and NOTCH1 control of squamous differentiation and cancer. J. Clin. Invest. 2014, 124:2260-2276.
18. Burtness B., Bauman J.E., Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013, 14:e302-e309.
19. Cai L., Ye Y., Jiang Q., Chen Y., Lyu X., Li J., Wang S., Liu T., Cai H., Yao K., et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat. Commun. 2015, 6:7353.
20. Campbell R.M., Tummino P.J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J. Clin. Invest. 2014, 124:64-69.
21. Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517:576-582.
22. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
23. Chung C.H., Parker J.S., Karaca G., Wu J., Funkhouser W.K., Moore D., Butterfoss D., Xiang D., Zanation A., Yin X., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5:489-500.
24. Chung C.H., Parker J.S., Ely K., Carter J., Yi Y., Murphy B.A., Ang K.K., El-Naggar A.K., Zanation A.M., Cmelak A.J., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006, 66:8210-8218.
25. Cox A.D., Der C.J., Philips M.R. Targeting RAS membrane association: back to the future for anti-RAS drug discovery?. Clin. Cancer Res. 2015, 21:1819-1827.
26. Croagh D., Frede J., Jones P.H., Kaur P., Partensky C., Phillips W.A. Esophageal stem cells and genetics/epigenetics in esophageal cancer. Ann. N. Y. Acad. Sci. 2014, 1325:8-14.
27. Crum C.P., McKeon F.D. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu. Rev. Pathol. 2010, 5:349-371.
28. Cruz F.D., Matushansky I. Solid tumor differentiation therapy - is it possible?. Oncotarget 2012, 3:559-567.
29. Daniely Y., Liao G., Dixon D., Linnoila R.I., Lori A., Randell S.H., Oren M., Jetten A.M. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am. J. Physiol. Cell Physiol 2004, 287:C171-C181.
30. de Wilde J., De-Castro Arce J., Snijders P.J., Meijer C.J., Rosl F., Steenbergen R.D. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol. 2008, 30:77-87.
31. DeMarini D.M. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res. 2004, 567:447-474.
32. Demehri S., Morimoto M., Holtzman M.J., Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009, 7:e1000067.
33. Demehri S., Turkoz A., Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009, 16:55-66.
34. Dienstmann R., Rodon J., Prat A., Perez-Garcia J., Adamo B., Felip E., Cortes J., Iafrate A.J., Nuciforo P., Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014, 25:552-563.
35. DiMaio D., Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001, 20:7866-7873.
36. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond) 2006, 110:525-541.
37. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 2015, 25(Suppl 1):2-23.
38. Dotto G.P. Notch tumor suppressor function. Oncogene 2008, 27:5115-5123.
39. Dotto G.P. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat. Rev. Cancer 2009, 9:587-595.
40. Dotto G.P. Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis. Cancer Res. 2011, 71:2029-2033.
41. Dotto G.P. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J. Clin. Invest. 2014, 124:1446-1453.
42. Dumortier A., Durham A.D., Di Piazza M., Vauclair S., Koch U., Ferrand G., Ferrero I., Demehri S., Song L.L., Farr A.G., et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of notch signaling in the murine skin. PLoS One 2010, 5:e9258.
43. Dziunycz P.J., Lefort K., Wu X., Freiberger S.N., Neu J., Djerbi N., Iotzowa-Weiss G., French L.E., Dotto G.P., Hofbauer G.F. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J. Invest. Dermatol. 2014, 134:1998-2004.
44. Egawa N., Egawa K., Griffin H., Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 2015, 7:3863-3890.
45. Elkabets M., Pazarentzos E., Juric D., Sheng Q., Pelossof R.A., Brook S., Benzaken A.O., Rodon J., Morse N., Yan J.J., et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015, 27:533-546.
46. Escuin-Ordinas H., Atefi M., Fu Y., Cass A., Ng C., Huang R.R., Yashar S., Comin-Anduix B., Avramis E., Cochran A.J., et al. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol. Oncol. 2014, 8:250-260.
47. Euvrard S., Kanitakis J., Pouteil-Noble C., Disant F., Dureau G., Finaz de Villaine J., Claudy A., Thivolet J. Aggressive squamous cell carcinomas in organ transplant recipients. Transpl. Proc. 1995, 27:1767-1768.
48. Ezhkova E., Pasolli H.A., Parker J.S., Stokes N., Su I.H., Hannon G., Tarakhovsky A., Fuchs E. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009, 136:1122-1135.
49. Facompre N., Nakagawa H., Herlyn M., Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Adv. Pharmacol. 2012, 65:235-265.
50. Ferone G., Thomason H.A., Antonini D., De Rosa L., Hu B., Gemei M., Zhou H., Ambrosio R., Rice D.P., Acampora D., et al. Mutant p63 causes defective expansion of ectodermal progenitor cells and impaired FGF signalling in AEC syndrome. EMBO Mol. Med. 2012, 4:192-205.
51. Franke A., Teyssen S., Singer M.V. Alcohol-related diseases of the esophagus and stomach. Dig. Dis. 2005, 23:204-213.
52. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
53. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:pl1.
54. Gao Y.B., Chen Z.L., Li J.G., Hu X.D., Shi X.J., Sun Z.M., Zhang F., Zhao Z.R., Li Z.T., Liu Z.Y., et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 2014, 46:1097-1102.
55. Garcia Campelo M.R., Alonso Curbera G., Aparicio Gallego G., Grande Pulido E., Anton Aparicio L.M. Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway. Clin. Transl. Oncol. 2011, 13:77-83.
56. Gonzalez-Perez A., Perez-Llamas C., Deu-Pons J., Tamborero D., Schroeder M.P., Jene-Sanz A., Santos A., Lopez-Bigas N. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 2013, 10:1081-1082.
57. Goudie D.R., D'Alessandro M., Merriman B., Lee H., Szeverenyi I., Avery S., O'Connor B.D., Nelson S.F., Coats S.E., Stewart A., et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat. Genet. 2011, 43:365-369.
58. Grabowski J., Saltzstein S.L., Sadler G., Blair S. Squamous cell carcinoma of the breast: a review of 177 cases. Am. Surg. 2009, 75:914-917.
59. Gross N.D., Bauman J.E., Gooding W.E., Denq W., Thomas S.M., Wang L., Chiosea S., Hood B.L., Flint M.S., Sun M., et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin. Cancer Res. 2014, 20:3289-3298.
60. Hafner C., van Oers J.M., Hartmann A., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E.C., Vogt T. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J. Invest. Dermatol. 2006, 126:2404-2407.
61. Hammerman P.S., Hayes D.N., Wilkerson M.D., Schultz N., Bose R., Chu A., Collisson E.A., Cope L., Creighton C.J., Getz G., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
62. He L., Torres-Lockhart K., Forster N., Ramakrishnan S., Greninger P., Garnett M.J., McDermott U., Rothenberg S.M., Benes C.H., Ellisen L.W. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov. 2013, 3:324-337.
63. Hedberg M.L., Goh G., Chiosea S.I., Bauman J.E., Freilino M.L., Zeng Y., Wang L., Diergaarde B.B., Gooding W.E., Lui V.W., et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J. Clin. Invest. 2016, 126:169-180.
64. Helman E., Lawrence M.S., Stewart C., Sougnez C., Getz G., Meyerson M. Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014, 24:1053-1063.
65. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N. Engl. J. Med. 2008, 359:1367-1380.
66. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Ng S., Leiserson M.D., Niu B., McLellan M.D., Uzunangelov V., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158:929-944.
67. Hu M., Yao J., Carroll D.K., Weremowicz S., Chen H., Carrasco D., Richardson A., Violette S., Nikolskaya T., Nikolsky Y., et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13:394-406.
68. Hu B., Castillo E., Harewood L., Ostano P., Reymond A., Dummer R., Raffoul W., Hoetzenecker W., Hofbauer G.F., Dotto G.P. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012, 149:1207-1220.
69. Hussain S.P., Hofseth L.J., Harris C.C. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001, 34(Suppl 2):S7-S15.
70. Iida M., Brand T.M., Campbell D.A., Starr M.M., Luthar N., Traynor A.M., Wheeler D.L. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol. Ther. 2013, 14:481-491.
71. Ishizumi T., McWilliams A., MacAulay C., Gazdar A., Lam S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 2010, 29:5-14.
72. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell Physiol 2003, 194:237-255.
73. Janes S.M., Watt F.M. New roles for integrins in squamous-cell carcinoma. Nat. Rev. Cancer 2006, 6:175-183.
74. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27:6920-6929.
75. Jenkins T.D., Nakagawa H., Rustgi A.K. The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma. Oncogene 1996, 13:1809-1813.
76. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
77. Justilien V., Walsh M.P., Ali S.A., Thompson E.A., Murray N.R., Fields A.P. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014, 25:139-151.
78. Kagawa S., Natsuizaka M., Whelan K.A., Facompre N., Naganuma S., Ohashi S., Kinugasa H., Egloff A.M., Basu D., Gimotty P.A., et al. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene 2014, 34:2347-2359.
79. Karakasheva T.A., Waldron T.J., Eruslanov E., Kim S.B., Lee J.S., O'Brien S., Hicks P.D., Basu D., Singhal S., Malavasi F., et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res. 2015, 75:4074-4085.
80. Kempkes B., Robertson E.S. Epstein-Barr virus latency: current and future perspectives. Curr. Opin. Virol. 2015, 14:138-144.
81. Kim Y., Hammerman P.S., Kim J., Yoon J.A., Lee Y., Sun J.M., Wilkerson M.D., Pedamallu C.S., Cibulskis K., Yoo Y.K., et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J. Clin. Oncol. 2014, 32:121-128.
82. Knoblich J.A. Asymmetric cell division: recent developments and their implications for tumour biology. Nat. Rev. Mol. Cell Biol. 2010, 11:849-860.
83. Kolev V., Mandinova A., Guinea-Viniegra J., Hu B., Lefort K., Lambertini C., Neel V., Dummer R., Wagner E.F., Dotto G.P. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 2008, 10:902-911.
84. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
85. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
86. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
87. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
88. Lechler T., Fuchs E. Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature 2005, 437:275-280.
89. Lechner M., Frampton G.M., Fenton T., Feber A., Palmer G., Jay A., Pillay N., Forster M., Cronin M.T., Lipson D., et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med. 2013, 5:49.
90. Lee C.S., Bhaduri A., Mah A., Johnson W.L., Ungewickell A., Aros C.J., Nguyen C.B., Rios E.J., Siprashvili Z., Straight A., et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat. Genet. 2014, 46:1060-1062.
91. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11:9-22.
92. Lefort K., Dotto G.P. Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression. Semin. Cancer Biol. 2004, 14:374-386.
93. Lefort K., Mandinova A., Ostano P., Kolev V., Calpini V., Kolfschoten I., Devgan V., Lieb J., Raffoul W., Hohl D., et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 2007, 21:562-577.
94. Li J.C., Zhao Y.H., Wang X.Y., Yang Y., Pan D.L., Qiu Z.D., Su Y., Pan J.J. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumour Biol. 2014, 35:651-657.
95. Liao R.G., Watanabe H., Meyerson M., Hammerman P.S. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012, 1:293-300.
96. Liao R.G., Jung J., Tchaicha J., Wilkerson M.D., Sivachenko A., Beauchamp E.M., Liu Q., Pugh T.J., Pedamallu C.S., Hayes D.N., et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013, 73:5195-5205.
97. Lin D.C., Hao J.J., Nagata Y., Xu L., Shang L., Meng X., Sato Y., Okuno Y., Varela A.M., Ding L.W., et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 2014, 46:467-473.
98. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jorcano J., Werner S., Sastre-Garau X., et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 2005, 14:1153-1160.
99. Ludmir E.B., Stephens S.J., Palta M., Willett C.G., Czito B.G. Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J. Gastrointest. Oncol. 2015, 6:287-295.
100. Machiels J.P., Haddad R.I., Fayette J., Licitra L.F., Tahara M., Vermorken J.B., Clement P.M., Gauler T., Cupissol D., Grau J.J., et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015, 16:583-594.
101. Malik R.D., Dakwar G., Hardee M.E., Sanfilippo N.J., Rosenkrantz A.B., Taneja S.S. Squamous cell carcinoma of the prostate. Rev. Urol. 2011, 13:56-60.
102. Mandinova A., Lefort K., Tommasi di Vignano A., Stonely W., Ostano P., Chiorino G., Iwaki H., Nakanishi J., Dotto G.P. The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response. EMBO J. 2008, 27:1243-1254.
103. Mandinova A., Kolev V., Neel V., Hu B., Stonely W., Lieb J., Wu X., Colli C., Han R., Pazin M., et al. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J. Clin. Invest. 2009, 119:3127-3137.
104. Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z., Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget 2014, 5:8906-8923.
105. Martincorena I., Roshan A., Gerstung M., Ellis P., Van Loo P., McLaren S., Wedge D.C., Fullam A., Alexandrov L.B., Tubio J.M., et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015, 348:880-886.
106. Mathelier A., Shi W., Wasserman W.W. Identification of altered cis-regulatory elements in human disease. Trends Genet. 2015, 31:67-76.
107. Matin R.N., Chikh A., Chong S.L., Mesher D., Graf M., Sanza P., Senatore V., Scatolini M., Moretti F., Leigh I.M., et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J. Exp. Med. 2013, 210:581-603.
108. McCabe M.T., Creasy C.L. EZH2 as a potential target in cancer therapy. Epigenomics 2014, 6:341-351.
109. Missero C., Antonini D. Crosstalk among p53 family members in cutaneous carcinoma. Exp. Dermatol. 2014, 23:143-146.
110. Missero C., Calautti E., Eckner R., Chin J., Tsai L.H., Livingston D.M., Dotto G.P. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA 1995, 92:5451-5455.
111. Modi B.G., Neustadter J., Binda E., Lewis J., Filler R.B., Roberts S.J., Kwong B.Y., Reddy S., Overton J.D., Galan A., et al. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012, 335:104-108.
112. Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25:304-317.
113. Muller E., Brault B., Holmes A., Legros A., Jeannot E., Campitelli M., Rousselin A., Goardon N., Frebourg T., Krieger S., et al. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Med. 2015, 4:1484-1493.
114. Naeem A.S., Zhu Y., Di W.L., Marmiroli S., O'Shaughnessy R.F. AKT1-mediated Lamin A/C degradation is required for nuclear degradation and normal epidermal terminal differentiation. Cell Death Differ. 2015, 22:2123-2132.
115. Narayanan D.L., Saladi R.N., Fox J.L. Ultraviolet radiation and skin cancer. Int. J. Dermatol. 2010, 49:978-986.
116. Oda Y., Hu L., Bul V., Elalieh H., Reddy J.K., Bikle D.D. Coactivator MED1 ablation in keratinocytes results in hair-cycling defects and epidermal alterations. J. Invest. Dermatol. 2012, 132:1075-1083.
117. Odegaard J.I., Hsieh M.H. Immune responses to Schistosoma haematobium infection. Parasite Immunol. 2014, 36:428-438.
118. Ohashi S., Natsuizaka M., Yashiro-Ohtani Y., Kalman R.A., Nakagawa M., Wu L., Klein-Szanto A.J., Herlyn M., Diehl J.A., Katz J.P., et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology 2010, 139:2113-2123.
119. Ojesina A.I., Lichtenstein L., Freeman S.S., Pedamallu C.S., Imaz-Rosshandler I., Pugh T.J., Cherniack A.D., Ambrogio L., Cibulskis K., Bertelsen B., et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014, 506:371-375.
120. Okano J., Gaslightwala I., Birnbaum M.J., Rustgi A.K., Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem. 2000, 275:30934-30942.
121. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
122. Oshimori N., Oristian D., Fuchs E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015, 160:963-976.
123. Pan Y., Lin M.H., Tian X., Cheng H.T., Gridley T., Shen J., Kopan R. gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev. Cell 2004, 7:731-743.
124. Papagerakis S., Pannone G., Zheng L., About I., Taqi N., Nguyen N.P., Matossian M., McAlpin B., Santoro A., McHugh J., et al. Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp. Cell Res. 2014, 325:111-129.
125. Paul M.K., Bisht B., Darmawan D.O., Chiou R., Ha V.L., Wallace W.D., Chon A.T., Hegab A.E., Grogan T., Elashoff D.A., et al. Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling. Cell Stem Cell 2014, 15:199-214.
126. Phillips B.J., Jenkinson P. Is ethanol genotoxic? A review of the published data. Mutagenesis 2001, 16:91-101.
127. Piccolo S., Enzo E., Montagner M. p63, Sharp1, and HIFs: master regulators of metastasis in triple-negative breast cancer. Cancer Res. 2013, 73:4978-4981.
128. Pickering C.R., Zhang J., Yoo S.Y., Bengtsson L., Moorthy S., Neskey D.M., Zhao M., Ortega Alves M.V., Chang K., Drummond J., et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013, 3:770-781.
129. Pickering C.R., Zhou J.H., Lee J.J., Drummond J.A., Peng S.A., Saade R.E., Tsai K.Y., Curry J.L., Tetzlaff M.T., Lai S.Y., et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin. Cancer Res. 2014, 20:6582-6592.
130. Pirker R. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. Curr. Opin. Oncol. 2015, 27:87-93.
131. Procopio M.G., Laszlo C., Al Labban D., Kim D.E., Bordignon P., Jo S.H., Goruppi S., Menietti E., Ostano P., Ala U., et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat. Cell Biol. 2015, 17:1193-1204.
132. Que J., Okubo T., Goldenring J.R., Nam K.T., Kurotani R., Morrisey E.E., Taranova O., Pevny L.H., Hogan B.L. Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development 2007, 134:2521-2531.
133. Raab-Traub N. Novel mechanisms of EBV-induced oncogenesis. Curr. Opin. Virol. 2012, 2:453-458.
134. Ramsey M.R., Wilson C., Ory B., Rothenberg S.M., Faquin W., Mills A.A., Ellisen L.W. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J. Clin. Invest. 2013, 123:3525-3538.
135. Ridley A.J., Whiteside J.R., McMillan T.J., Allinson S.L. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int. J. Radiat. Biol. 2009, 85:177-195.
136. Robinson K.W., Sandler A.B. EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. Curr. Oncol. Rep. 2013, 15:396-404.
137. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., Lichinitser M., Dummer R., Grange F., Mortier L., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015, 372:30-39.
138. Rustgi A.K., El-Serag H.B. Esophageal carcinoma. N. Engl. J. Med. 2014, 371:2499-2509.
139. Saburi S., Hester I., Goodrich L., McNeill H. Functional interactions between Fat family cadherins in tissue morphogenesis and planar polarity. Development 2012, 139:1806-1820.
140. Sadeqzadeh E., de Bock C.E., Thorne R.F. Sleeping giants: emerging roles for the fat cadherins in health and disease. Med. Res. Rev. 2014, 34:190-221.
141. Saoncella S., Tassone B., Deklic E., Avolio F., Jon C., Tornillo G., De Luca E., Di Iorio E., Piva R., Cabodi S., et al. Nuclear Akt2 opposes limbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. Stem Cells 2014, 32:754-769.
142. Schafer M., Werner S. Nrf2-A regulator of keratinocyte redox signaling. Free Radic. Biol. Med. 2015, 88:243-252.
143. Schrock A., Bode M., Goke F.J., Bareiss P.M., Schairer R., Wang H., Weichert W., Franzen A., Kirsten R., van Bremen T., et al. Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis 2014, 35:1636-1642.
144. Schroeder M.P., Rubio-Perez C., Tamborero D., Gonzalez-Perez A., Lopez-Bigas N. Oncodrive ROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics 2014, 30:i549-i555.
145. Schwaederle M., Elkin S.K., Tomson B.N., Carter J.L., Kurzrock R. Squamousness: next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle 2015, 14:2355-2361.
146. Seiwert T.Y., Zuo Z., Keck M.K., Khattri A., Pedamallu C.S., Stricker T., Brown C., Pugh T.J., Stojanov P., Cho J., et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 2015, 21:632-641.
147. Shah K.M., Young L.S. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin. Microbiol. Infect. 2009, 15:982-988.
148. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
149. Song Y., Li L., Ou Y., Gao Z., Li E., Li X., Zhang W., Wang J., Xu L., Zhou Y., et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014, 509:91-95.
150. Soria J.C., Felip E., Cobo M., Lu S., Syrigos K., Lee K.H., Goker E., Georgoulias V., Li W., Isla D., et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015, 16:897-907.
151. Sottoriva A., Kang H., Ma Z., Graham T.A., Salomon M.P., Zhao J., Marjoram P., Siegmund K., Press M.F., Shibata D., et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 2015, 47:209-216.
152. South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y., Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J. Invest. Dermatol. 2014, 134:2630-2638.
153. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
154. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366:207-215.
155. Sun W., Gaykalova D.A., Ochs M.F., Mambo E., Arnaoutakis D., Liu Y., Loyo M., Agrawal N., Howard J., Li R., et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014, 74:1091-1104.
156. Talora C., Sgroi D.C., Crum C.P., Dotto G.P. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 2002, 16:2252-2263.
157. Talora C., Cialfi S., Segatto O., Morrone S., Kim Choi J., Frati L., Paolo Dotto G., Gulino A., Screpanti I. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp. Cell Res. 2005, 305:343-354.
158. Taylor P.R., Abnet C.C., Dawsey S.M. Squamous dysplasia-the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2013, 22:540-552.
159. Tomasetti C., Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015, 347:78-81.
160. Tomasetti C., Vogelstein B., Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl. Acad. Sci. USA 2013, 110:1999-2004.
161. Toschi L., Finocchiaro G., Nguyen T.T., Skokan M.C., Giordano L., Gianoncelli L., Perrino M., Siracusano L., Di Tommaso L., Infante M., et al. Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PLoS One 2014, 9:e95303.
162. Tubio J.M., Li Y., Ju Y.S., Martincorena I., Cooke S.L., Tojo M., Gundem G., Pipinikas C.P., Zamora J., Raine K., et al. Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science 2014, 345:1251343.
163. Tunio M.A., Al Asiri M., Fagih M., Akasha R. Primary squamous cell carcinoma of thyroid: a case report and review of literature. Head Neck Oncol. 2012, 4:8.
164. Waldron T.J., Quatromoni J.G., Karakasheva T.A., Singhal S., Rustgi A.K. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology 2013, 2:e24117.
165. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 2011, 108:17761-17766.
166. Wang F., Marshall C.B., Ikura M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol. Life Sci. 2013, 70:3989-4008.
167. Wang R., Wang L., Li Y., Hu H., Shen L., Shen X., Pan Y., Ye T., Zhang Y., Luo X., et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin. Cancer Res. 2014, 20:4107-4114.
168. Watanabe H., Ma Q., Peng S., Adelmant G., Swain D., Song W., Fox C., Francis J.M., Pedamallu C.S., DeLuca D.S., et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J. Clin. Invest. 2014, 124:1636-1645.
169. Weina K., Utikal J. SOX2 and cancer: current research and its implications in the clinic. Clin. Transl. Med. 2014, 3:19.
170. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
171. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
172. Wischermann K., Popp S., Moshir S., Scharfetter-Kochanek K., Wlaschek M., de Gruijl F., Hartschuh W., Greinert R., Volkmer B., Faust A., et al. UVA radiation causes DNA strand breaks, chromosomal aberrations and tumorigenic transformation in HaCaT skin keratinocytes. Oncogene 2008, 27:4269-4280.
173. Woolgar J.A., Triantafyllou A. Squamous cell carcinoma and precursor lesions: clinical pathology. Periodontol 2000 2011, 57:51-72.
174. Wu X., Nguyen B.C., Dziunycz P., Chang S., Brooks Y., Lefort K., Hofbauer G.F., Dotto G.P. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010, 465:368-372.
175. Wu Y.M., Su F., Kalyana-Sundaram S., Khazanov N., Ateeq B., Cao X., Lonigro R.J., Vats P., Wang R., Lin S.F., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013, 3:636-647.
176. Wu Y., Zhang L., Zhang L., Wang Y., Li H., Ren X., Wei F., Yu W., Liu T., Wang X., et al. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int. J. Oncol. 2015, 46:2586-2594.
177. Xie Q., Wang H., Heilman E.R., Walsh M.G., Haseeb M.A., Gupta R. Increased expression of enhancer of Zeste Homolog 2 (EZH2) differentiates squamous cell carcinoma from normal skin and actinic keratosis. Eur. J. Dermatol. 2014, 24:41-45.
178. Xu C., Fillmore C.M., Koyama S., Wu H., Zhao Y., Chen Z., Herter-Sprie G.S., Akbay E.A., Tchaicha J.H., Altabef A., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25:590-604.
179. Xu X., Huang L., Futtner C., Schwab B., Rampersad R.R., Lu Y., Sporn T.A., Hogan B.L., Onaitis M.W. The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. Genes Dev. 2014, 28:1929-1939.
180. Yamaguchi H., Hung M.C. Regulation and role of EZH2 in cancer. Cancer Res. Treat. 2014, 46:209-222.
181. Yang Y., Nakagawa H., Tetreault M.P., Billig J., Victor N., Goyal A., Sepulveda A.R., Katz J.P. Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res. 2011, 71:6475-6484.
182. Yang H., Schramek D., Adam R.C., Keyes B.E., Wang P., Zheng D., Fuchs E. ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. Elife 2015, 4. 10.7554/eLife.10870.
183. Yugawa T., Handa K., Narisawa-Saito M., Ohno S., Fujita M., Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell Biol. 2007, 27:3732-3742.
184. Zhang L., Zhou Y., Cheng C., Cui H., Cheng L., Kong P., Wang J., Li Y., Chen W., Song B., et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 2015, 96:597-611.